Increased intracellular doxorubicin by anti-Fas monoclonal antibody: a mechanism that enhances the cytotoxicity in renal cell carcinoma cells

Author： Wu X.-X. Kakehi Y. Mizutani Y. Terachi T. Ogawa O.

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.57, Iss.5, 2001-05, pp. : 993-998

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II trial with monoclonal antibody WX-G250 in advanced renal cell carcinoma

By Bleumer I. Beck J. Hofmann R. Kruit W. Warnaar S. Mala C. Ullrich S. Huber C. Debruyne F.M.J. Oosterwijk E. Mulders P.F.A.

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 112-112

Elsevier

Access to resources Recommend Favorite

Antibody therapy in renal cell carcinoma

By Oosterwijk Egbert

World Journal of Urology, Vol. 26, Iss. 2, 2008-04 ,pp. : 141-146

Springer Publishing Company

Access to resources Recommend Favorite

Micelle delivery of doxorubicin increases cytotoxicity to prostate carcinoma cells

By McNealy Tamara

Urological Research, Vol. 32, Iss. 4, 2004-08 ,pp. : 255-260

Springer Publishing Company

Access to resources Recommend Favorite

Suppression of clusterin expression enhanced cisplatin-induced cytotoxicity on renal cell carcinoma cells

By Lee C.-H. Jin R.J. Kwak C. Jeong H. Park M.S. Lee N.K. Lee S.E.

Urology, Vol. 60, Iss. 3, 2002-09 ,pp. : 516-520

Elsevier

Access to resources Recommend Favorite

Increased incidence of serendipitously discovered renal cell carcinoma

By Jayson M. Sanders H.

Urology, Vol. 51, Iss. 2, 1998-02 ,pp. : 203-205

Elsevier

Access to resources Recommend Favorite